1. Others
  2. Others

Inosine 

Cat. No.: HY-N0092 Purity: >98.0%
Data Sheet SDS Handling Instructions

Inosine, an endogenous purine nucleoside, has immunomodulatory, neuroprotective, and analgesic properties.

For research use only. We do not sell to patients.
Inosine Chemical Structure

Inosine Chemical Structure

CAS No. : 58-63-9

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $55 In-stock
1 g $50 In-stock
10 g $60 In-stock
25 g $70 In-stock
100 g $200 In-stock
> 100 g   Get quote  

* Please select Quantity before adding items.

Customer Review

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Inosine, an endogenous purine nucleoside, has immunomodulatory, neuroprotective, and analgesic properties. In vitro: Inosine has been shown to stimulate axonal growth in cell culture and promote corticospinal tract axons to sprout collateral branches after stroke, spinal cord injury and TBI in rodent models.[1] Inosine dose-dependently stimulates cAMP production mediated through the A2AR. Inosine dose-dependently induces A2AR-mediated ERK1/2 phosphorylation.[2] In vivo: The reference for Inosine is 1 or 10 mg/kg, i.p. Preventive treatment with inosine inhibits the development and progression of EAE in C57Bl/6 mice. neuroinflammation and demyelinating processes are blocked by inosine treatment. Additionally, inosine consistently inhibits IL-17 levels in peripheral lymphoid tissue, as well as IL-4 levels and A2AR up-regulation in the spinal cord, likely, through an ERK1-independent pathway. [3] inosine acting through adenosine receptors (ARs) exerts a wide range of anti-inflammatory and immunomodulatory effects in vivo. [2]

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT02614469 Michael Alan Schwarzschild|Michael J. Fox Foundation for Parkinson's Research|The Parkinson Alliance|Massachusetts General Hospital Healthy March 2015 Phase 1
NCT02288091 Massachusetts General Hospital|The Salah Foundation|MGH cure ALS Fund Amyotrophic Lateral Sclerosis January 2015 Phase 1
NCT00067327 National Center for Complementary and Integrative Health (NCCIH) Multiple Sclerosis, Relapsing-Remitting February 2002 Phase 2
NCT02642393 Michael Alan Schwarzschild|The Parkinson Study Group|Michael J. Fox Foundation for Parkinson's Research|University of Rochester|National Institute of Neurological Disorders and Stroke (NINDS)|Massachusetts General Hospital Parkinson's Disease June 2016 Phase 3
NCT00833690 The Parkinson Study Group|Massachusetts General Hospital|Harvard School of Public Health|University of Rochester|Michael J. Fox Foundation for Parkinson's Research Parkinson Disease June 2009 Phase 2
NCT03168711 Massachusetts General Hospital|The Salah Foundation|MGH cure ALS Fund Amyotrophic Lateral Sclerosis July 2017 Phase 2
NCT00002060 Newport Pharmaceuticals International|NIH AIDS Clinical Trials Information Service HIV Infections
NCT00002297 Newport Pharmaceuticals International|NIH AIDS Clinical Trials Information Service Lymphatic Disease|HIV Infections
NCT00002296 Newport Pharmaceuticals International|NIH AIDS Clinical Trials Information Service Lymphatic Disease|HIV Infections
NCT00002061 Newport Pharmaceuticals International|NIH AIDS Clinical Trials Information Service Lymphatic Disease|HIV Infections
NCT00002059 Newport Pharmaceuticals International|NIH AIDS Clinical Trials Information Service HIV Infections
NCT00002295 Newport Pharmaceuticals International|NIH AIDS Clinical Trials Information Service HIV Infections
NCT00000699 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 1
NCT00893724 Mid-Atlantic Retina Consultations, Inc.|West Virginia University Neovascular Age-related Macular Degeneration|Diabetic Macular Edema June 2009
View MoreCollapse
References
M.Wt

268.23

Formula

C₁₀H₁₂N₄O₅

CAS No.

58-63-9

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: 9.66 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Inosine
Cat. No.:
HY-N0092
Quantity: